- Home
- YMM vs ABVX Comparison
YMM vs ABVX Comparison
Compare YMM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YMM | ABVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | YMM | ABVX |
|---|---|---|
| Price | $9.96 | $122.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $12.00 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 11.1M | 1.8M |
| Earning Date | 03-04-2026 | 08-11-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | ★ 29.34 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $1,751,813,549.00 | $6,231,374.00 |
| Revenue This Year | $11.40 | $6.80 |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | ★ 19.09 | N/A |
| 52 Week Low | $9.45 | $4.77 |
| 52 Week High | $14.07 | $148.83 |
Technical Indicators
Market Signals| Indicator | YMM | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 50.00 |
| Support Level | $9.76 | $113.64 |
| Resistance Level | $10.24 | $122.50 |
| Average True Range (ATR) | 0.45 | 8.60 |
| MACD | -0.06 | -0.99 |
| Stochastic Oscillator | 17.07 | 43.88 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.